688399 硕世生物
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)0.101-0.060-10.40857.89456.807
总资产报酬率 ROA (%)0.085-0.052-8.49843.57241.309
投入资产回报率 ROIC (%)0.089-0.055-9.78253.92352.149

边际利润分析
销售毛利率 (%)63.21362.25763.91260.61669.132
营业利润率 (%)2.7012.521-90.54538.84049.133
息税前利润/营业总收入 (%)3.474-8.234-105.00738.02548.281
净利润/营业总收入 (%)1.224-0.573-92.71633.02642.029

收益指标分析
经营活动净收益/利润总额(%)-691.519-1,692.80757.415114.61295.566
价值变动净收益/利润总额(%)522.63219.870-3.9142.4182.116
营业外收支净额/利润总额(%)2.401-110.5112.825-0.514-0.225

偿债能力分析
流动比率 (X)3.3185.8167.4473.9772.967
速动比率 (X)3.2195.6347.1893.7242.675
资产负债率 (%)18.66613.08312.83322.75327.516
带息债务/全部投入资本 (%)11.8835.8052.7711.0214.917
股东权益/带息债务 (%)715.1131,564.2443,372.0649,250.3971,855.366
股东权益/负债合计 (%)435.743664.322679.242339.502263.420
利息保障倍数 (X)4.9150.8738.876-61.704-65.049

营运能力分析
应收账款周转天数 (天)54.82183.684300.33629.48331.703
存货周转天数 (天)171.296219.492408.40140.18284.872